NYSE:AGN - Allergan Stock Price, Forecast & News

Allergan trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

Allergan declared a quarterly dividend on Friday, October 25th. Investors of record on Wednesday, November 13th will be given a dividend of $0.74 per share on Friday, December 13th. This represents a $2.96 annualized dividend and a dividend yield of 1.57%. The ex-dividend date is Tuesday, November 12th. View Allergan's Dividend History.

Allergan announced that its Board of Directors has authorized a stock repurchase plan on Tuesday, January 29th 2019, which permits the company to buyback $2,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 4.1% of its stock through open market purchases. Stock buyback plans are often an indication that the company's leadership believes its stock is undervalued.

Allergan plc (NYSE:AGN) released its quarterly earnings results on Tuesday, November, 5th. The company reported $4.25 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $4.25. The business had revenue of $4.03 billion for the quarter, compared to analyst estimates of $3.88 billion. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. Allergan's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.25 EPS. View Allergan's Earnings History.

Allergan is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Allergan.

Allergan issued an update on its FY19 earnings guidance on Tuesday, November, 5th. The company provided earnings per share guidance of >$16.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.74. The company issued revenue guidance of $15.6-15.8 billion, compared to the consensus revenue estimate of $15.58 billion.

20 brokerages have issued 1 year price targets for Allergan's stock. Their forecasts range from $144.95 to $203.00. On average, they anticipate Allergan's stock price to reach $175.90 in the next twelve months. This suggests that the stock has a possible downside of 6.6%. View Analyst Price Targets for Allergan.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergan in the last year. There are currently 16 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Allergan.

News stories about AGN stock have trended neutral recently, according to InfoTrie. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allergan earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Allergan.

Allergan saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 13,770,000 shares, an increase of 28.9% from the November 14th total of 10,680,000 shares. Based on an average daily volume of 2,330,000 shares, the short-interest ratio is presently 5.9 days. Approximately 4.2% of the shares of the company are short sold. View Allergan's Current Options Chain.

Some companies that are related to Allergan include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Zogenix (ZGNX) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergan investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Transocean (RIG) and United Rentals (URI).

Allergan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.51%), Third Point LLC (1.10%), Assenagon Asset Management S.A. (0.54%), Boussard & Gavaudan Investment Management LLP (0.40%), Sachem Head Capital Management LP (0.39%) and Newport Trust Co (0.38%). Company insiders that own Allergan stock include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado, Matthew M Walsh and William Meury. View Institutional Ownership Trends for Allergan.

AGN stock was sold by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., State of New Jersey Common Pension Fund D, Robeco Institutional Asset Management B.V., Metropolis Capital Ltd, Russell Investments Group Ltd., Great West Life Assurance Co. Can, California State Teachers Retirement System and Envestnet Asset Management Inc.. View Insider Buying and Selling for Allergan.

AGN stock was bought by a variety of institutional investors in the last quarter, including Third Point LLC, State Street Corp, Assenagon Asset Management S.A., Boussard & Gavaudan Investment Management LLP, Sachem Head Capital Management LP, Canyon Capital Advisors LLC, York Capital Management Global Advisors LLC and Tibra Equities Europe Ltd. Company insiders that have bought Allergan stock in the last two years include Brent L Saunders, Christopher J Coughlin, Joseph H Boccuzi, Maria Teresa Hilado and Matthew M Walsh. View Insider Buying and Selling for Allergan.

Shares of AGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AGN stock can currently be purchased for approximately $188.34.

Allergan has a market capitalization of $61.83 billion and generates $15.79 billion in revenue each year. The company earns $-5,096,400,000.00 in net income (profit) each year or $16.69 on an earnings per share basis. Allergan employs 16,900 workers across the globe.View Additional Information About Allergan.

The official website for Allergan is http://www.allergan.com/.

Allergan's mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 862-261-7000 or via email at [email protected]